In ISOS we propose to develop the first biomedical product for the in-situ fabrication and auto-renewed delivery of therapeutic compounds employing large ecosystems of probiotic genetically engineered bacteria (GEB) integrated in a biomaterial-based bioreactor.
This project is funded by the European Union’s EIC-Pathfinder Programme, under the Grant Agreement number 101130454
ISOS presents a visionary approach to in situ fabrication and auto-renewed delivery of therapeutic compounds.
ISOS aims to seamlessly integrate genetically engineered bacteria into a biomaterial-based bioreactor.
ISOS targets the wet form of age-related macular degeneration, proposing a genetically engineered bacteria bioreactor to replace frequent injections against vascular endothelial growth factor.
This initiative holds the promise of transforming prolonged treatments into personalised, efficient and minimally invasive healthcare experiences.
